CPhI China , leading exhibition for the medical & pharmaceutical industry and being organized by UBM Asia Ltd ,will be held from June 21 to 23, 2011 at Shanghai New International Expo Centre (SNIEC) in China.
The latest edition is expected to be the largest edition of CPhI China and has co-located events – P-MEC China, which covers pharma machinery and equipment, ICSE China, which looks at outsourcing solutions, BioPh China, which showcases the biopharma sector and the LABWorld pavilion for laboratory, analytical and biotechnology instrumentation technologies.
CPhI China has been organized in China since its launch in 2001.After a successful 2010 event, CPhI China is expected to grow further in 2011. The events are projected to host over 27,000 attendees with 1,700 exhibitors, including many key players in all aspects of China’s expanding pharma industry. The events are the most international pharma industry events in China and serve to act as a conduit for attendees to gain accurate market knowledge and competitor intelligence.
“China’s pharma market is expected to become the third largest in the world in 2011. The strength of China’s industry allows the brands to consistently deliver a quality event in a growing market that is also forward thinking,” Annemieke Timmers, Brand Director for CPhI noted. “China is at the centre of Health Reform. The government has recently provided US$ 125bn in incremental funding to increase medical insurance coverage to all city residents and 90% of the rural population1.”
CPhI China and co-located events will have a few new introductions in 2011. Most notable, is the addition of the first modular conference program for the events, with relevant topics in the current market, such as API sourcing strategy, compliance, reduction of cost and maximizing competitive strategies in generics. Also new is the addition of LABWorld pavilion to the P-MEC event which will cater to small scale laboratory and analysis needs. This new pavilion will couple with P-MEC to host over 320 suppliers.
“It is clear that China’s pharma market growth looks very positive for the future based on past figures and current projections. Within the past five years, markets in second and third-tier cities within China have grown 28% and 47.5% respectively,” commented Haf Cennydd, Event Director of ICSE/P-MEC/BioPh/LABWorld China.
“We have structured the events to offer specific solutions for the current market demands. For example, introductions such as LABWorld, located in the P-MEC event have been tailored to the lab and analytics sectors of the pharmaceutical market”, she added.